Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 1,521 Cr.
- Current Price ₹ 248
- High / Low ₹ 263 / 112
- Stock P/E
- Book Value ₹ 53.7
- Dividend Yield 0.00 %
- ROCE 4.08 %
- ROE 1.08 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 4.61 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -15.8% over last 3 years.
- Contingent liabilities of Rs.640 Cr.
- Earnings include an other income of Rs.25.4 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
596 | 498 | 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | 327 | |
653 | 586 | 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | 330 | |
Operating Profit | -57 | -88 | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 | -3 |
OPM % | -10% | -18% | 10% | 17% | 13% | -4% | -152% | -57% | 0% | -31% | -24% | 4% | -1% |
-5 | 304 | 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | 25 | |
Interest | 106 | 148 | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 | 14 |
Depreciation | 84 | 69 | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 | 21 |
Profit before tax | -251 | -0 | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 | -12 |
Tax % | -8% | 0% | 3% | 38% | -14% | 17% | 29% | 13% | 12% | 0% | 40% | 16% | |
-230 | -0 | -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | -12 | |
EPS in Rs | -37.54 | -0.07 | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 | -1.88 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -3% |
5 Years: | 30% |
3 Years: | 2% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 15% |
3 Years: | 30% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 15% |
3 Years: | -6% |
1 Year: | 78% |
Return on Equity | |
---|---|
10 Years: | -17% |
5 Years: | -13% |
3 Years: | -16% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 555 | 556 | 517 | 518 | 450 | 382 | 412 | 855 | 502 | 409 | 320 | 323 |
922 | 990 | 1,031 | 1,035 | 1,023 | 970 | 689 | 67 | 65 | 84 | 102 | 125 | |
197 | 334 | 325 | 248 | 303 | 316 | 335 | 211 | 217 | 263 | 296 | 300 | |
Total Liabilities | 1,680 | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 |
959 | 1,086 | 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 449 | |
CWIP | 28 | 26 | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 71 |
Investments | 272 | 394 | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 |
422 | 380 | 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | |
Total Assets | 1,680 | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-39 | 53 | 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 37 | |
-14 | -18 | -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -51 | |
55 | -38 | -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | |
Net Cash Flow | 1 | -3 | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 42 | 66 | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 |
Inventory Days | 316 | 310 | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 |
Days Payable | 216 | 397 | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 316 |
Cash Conversion Cycle | 141 | -20 | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -27 |
Working Capital Days | 65 | -143 | -57 | 43 | 18 | -297 | 215 | 900 | 8 | -63 | -138 | -97 |
ROCE % | -9% | -9% | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% | 4% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Copies of the public notice, requesting shareholders to register their remail addresses with the Company in connection with ensuing 40th Annual General Meeting of the …
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ('SEBI LODR Regulations') 20 Aug
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Aug - Newspaper copies of the Extract of Statement of Unaudited Financial Results for the quarter ended June 30, 2024, published in the newspapers on August 15, …
- Disclosure Of Audit Committee Views On Resignation Of The Statutory Auditors Of The Company'S Material Subsidiary, Panacea Biotec Pharma Limited 14 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Aug - Press Release on initiation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix